Disc Medicine Advances DISC-3405 in Polycythemia Vera
WATERTOWN, Mass. — September 9, 2026 Disc Medicine, Inc. presented positive initial results from the Phase 2 RESTORE-PV trial...
polycythemia vera
Advertisement
AN2 Therapeutics Highlights Epetraborole Data for PV at SOHO
MENLO PARK, Calif., August 31, 2026 AN2 Therapeutics, Inc. announced that four abstracts featuring clinical and translational data for...
Protagonist Therapeutics Wins FDA Approval for MIMRYLO
Protagonist Therapeutics, Newark, California, August 28, 2026 Protagonist Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
PharmaEssentia Wins Canadian Approval for BESREMi in Rare Blood Cancer
BURLINGTON, Mass., July 6, 2026 PharmaEssentia Corporation announced that its wholly owned Canadian subsidiary, FORUS Therapeutics Inc., has received...
PharmaEssentia Secures FDA Approval for BESREMi Pen in Polycythemia Vera
BURLINGTON, Mass., June 26, 2026 PharmaEssentia USA Corporation announced that the U.S. Food and Drug Administration (FDA) has approved...
Advertisements
Incyte Corporation Wins FDA Approval for Jakafi XR
WILMINGTON, Del., May 1, 2026 Incyte Corporation has secured U.S. Food and Drug Administration (FDA) approval for Jakafi XR™...
Eli Lilly to Acquire Ajax Therapeutics in $2.3B Oncology Deal
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
Advertisement
